The latest price target for Supernus Pharmaceuticals (NASDAQ:SUPN) was reported by Cantor Fitzgerald on February 19, 2025. The analyst firm set a price target for $36.00 expecting SUPN to rise to within 12 months (a possible 10.33% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Supernus Pharmaceuticals (NASDAQ:SUPN) was provided by Cantor Fitzgerald, and Supernus Pharmaceuticals downgraded their neutral rating.

There is no last upgrade for Supernus Pharmaceuticals

The last downgrade for Supernus Pharmaceuticals Inc happened on February 19, 2025 when Cantor Fitzgerald changed their price target from $57 to $36 for Supernus Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Supernus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Supernus Pharmaceuticals was filed on February 19, 2025 so you should expect the next rating to be made available sometime around February 19, 2026.

While ratings are subjective and will change, the latest Supernus Pharmaceuticals (SUPN) rating was a downgraded with a price target of $57.00 to $36.00. The current price Supernus Pharmaceuticals (SUPN) is trading at is $32.63, which is out of the analyst’s predicted range.